Related Experiment Video
Updated: Jun 25, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.7K
Clopidogrel-Induced Interstitial Lung Disease: A Case Report.
Jin An1, Seung Hwan Lee2, Boksoon Chang1
1Department of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Therapeutics and Clinical Risk Management
|July 21, 2021
Summary
Clopidogrel, a common antiplatelet medication, can rarely cause interstitial lung disease. Prompt withdrawal of clopidogrel and steroid treatment led to patient recovery, highlighting the importance of recognizing this adverse effect.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Dual antiplatelet therapy with aspirin and clopidogrel is crucial for preventing recurrent ischemic events in patients with intracranial arterial stenosis.
- Clopidogrel, while effective, carries a risk of adverse effects, primarily hemorrhagic complications.
- Interstitial lung disease (ILD) is a recognized, albeit rare, potential adverse reaction to clopidogrel.
Observation:
- A 79-year-old female patient on dual antiplatelet therapy presented with acute dyspnea.
- Chest CT revealed bilateral peribronchial ground-glass opacity and reticulation, with negative infectious workup.
- Symptoms improved significantly after clopidogrel withdrawal and initiation of steroid therapy.
Findings:
- The patient's presentation and subsequent recovery strongly suggest clopidogrel-induced interstitial lung disease.
- This case highlights a rare but serious pulmonary complication associated with clopidogrel use.
- Early recognition and management, including drug discontinuation and corticosteroid administration, are key to favorable outcomes.
Implications:
- Clinicians should consider clopidogrel-induced ILD in patients presenting with unexplained pulmonary symptoms while on this medication.
- Awareness of this rare adverse effect is critical for timely diagnosis and appropriate patient management.
- This case underscores the need for vigilant monitoring of potential drug-induced lung injuries in clinical practice.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...